Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
about
Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.Toward a Cancer Drug of Fungal OriginTreatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Sunitinib for the treatment of thyroid cancer.Incidence and risk of regorafenib-induced hepatotoxicity.Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.
P2860
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Risk of hematologic toxicities ...... atic review and meta-analysis.
@ast
Risk of hematologic toxicities ...... atic review and meta-analysis.
@en
type
label
Risk of hematologic toxicities ...... atic review and meta-analysis.
@ast
Risk of hematologic toxicities ...... atic review and meta-analysis.
@en
prefLabel
Risk of hematologic toxicities ...... atic review and meta-analysis.
@ast
Risk of hematologic toxicities ...... atic review and meta-analysis.
@en
P2093
P1476
Risk of hematologic toxicities ...... atic review and meta-analysis.
@en
P2093
Asma Latif
Matthew D Galsky
Tomohiro Funakoshi
P304
P356
10.1016/J.CTRV.2013.01.004
P577
2013-02-28T00:00:00Z